new tirzepatide drug F.D.A. Approves Obesity That Will Compete With Wegovy FDA approves new version of

Book an appointment with your healthcare provider, dietitian or psychologist for in-person or virtual visits

Our team is known for their attentive and well-informed guidance, making us an ideal choice for those considering these increasingly common weight loss solutions

doi: 10.1001/jama.2020.3514 2

According to the FDA labeling, there are no clinically meaningful differences in absorption between these approved injection sites when proper technique is used

30 days average time to launch (vs

Inclusion Criteria Inclusion Criteria All of the following must be met for tirzepatide to be prescribed (1-5): Diagnosis of Type II diabetes A BMI of 25 or greater Inadequate glycemic control on at least 1mg of semaglutide injection plus two or more glucose-lowering drugs Change is needed to achieve the goal of an A1C below 1%